| Ms Gretchen Blue Schwinn, CNM | |
|
1660 Delaware St, Longview, WA 98632-2310 | |
| (360) 414-2800 | |
| (360) 414-2803 |
| Full Name | Ms Gretchen Blue Schwinn |
|---|---|
| Gender | Female |
| Speciality | Certified Nurse Midwife (cnm) |
| Experience | 13 Years |
| Location | 1660 Delaware St, Longview, Washington |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1548527369 | NPI | - | NPPES |
| 500705140 | Medicaid | OR | |
| 2058425 | Medicaid | WA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367A00000X | Advanced Practice Midwife | AP60255202 (Washington) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Peacehealth St John Medical Center | Longview, WA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Peacehealth | 5890689293 | 182 |
News Archive
Professor Matthew Disney of the Department of Chemistry on the Florida campus of The Scripps Research Institute, together with scientists from Mayo Clinic's Florida campus and Johns Hopkins School of Medicine, has been awarded $7.2 million from the National Institute of Neurological Disorders and Stroke of The National Institutes of Health to create new RNA-based treatments for the most common form of amyotrophic lateral sclerosis (ALS), as well as a type of frontotemporal dementia (FTD).
A pair of neurologists at Nationwide Children's Hospital, Monica P. Islam, MD, and E. Steve Roach, MD, are the editors behind "Neurocutaneous Syndromes," a recently published book that highlights the insights of neurocutaneous syndromes research and shows that "classic doctoring" still has a big role to play in diagnosis and treatment.
Depomed, Inc. today announced top line results from the Phase III clinical trial of its Ciprofloxacin GR, an extended release formulation of ciprofloxacin HCl, which is used to treat urinary tract infections. The data confirmed Phase II results, demonstrating that Depomed's once-daily Ciprofloxacin GR eliminated the organisms responsible for urinary tract infections as effectively as twice-daily CIPRO(R), but with fewer gastrointestinal side effects, specifically fewer incidences of nausea and diarrhea.
In this Kaiser Health News consumer column, Michelle Andrews writes: "High-deductible health plans and the health savings accounts (HSAs) that link to them are becoming a familiar fixture on the insurance landscape, even though they get mixed reviews from many consumers and health-policy experts" (Kaiser Health News).
Depression is associated with an increased risk of developing kidney failure in the future, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society Nephrology.
› Verified 8 days ago
| Entity Name | Peacehealth |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1720056187 PECOS PAC ID: 5890689293 Enrollment ID: O20040209000272 |
News Archive
Professor Matthew Disney of the Department of Chemistry on the Florida campus of The Scripps Research Institute, together with scientists from Mayo Clinic's Florida campus and Johns Hopkins School of Medicine, has been awarded $7.2 million from the National Institute of Neurological Disorders and Stroke of The National Institutes of Health to create new RNA-based treatments for the most common form of amyotrophic lateral sclerosis (ALS), as well as a type of frontotemporal dementia (FTD).
A pair of neurologists at Nationwide Children's Hospital, Monica P. Islam, MD, and E. Steve Roach, MD, are the editors behind "Neurocutaneous Syndromes," a recently published book that highlights the insights of neurocutaneous syndromes research and shows that "classic doctoring" still has a big role to play in diagnosis and treatment.
Depomed, Inc. today announced top line results from the Phase III clinical trial of its Ciprofloxacin GR, an extended release formulation of ciprofloxacin HCl, which is used to treat urinary tract infections. The data confirmed Phase II results, demonstrating that Depomed's once-daily Ciprofloxacin GR eliminated the organisms responsible for urinary tract infections as effectively as twice-daily CIPRO(R), but with fewer gastrointestinal side effects, specifically fewer incidences of nausea and diarrhea.
In this Kaiser Health News consumer column, Michelle Andrews writes: "High-deductible health plans and the health savings accounts (HSAs) that link to them are becoming a familiar fixture on the insurance landscape, even though they get mixed reviews from many consumers and health-policy experts" (Kaiser Health News).
Depression is associated with an increased risk of developing kidney failure in the future, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society Nephrology.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ms Gretchen Blue Schwinn, CNM 1115 Se 164th Ave, Dept. 358, Vancouver, WA 98683-9324 Ph: (360) 729-1462 | Ms Gretchen Blue Schwinn, CNM 1660 Delaware St, Longview, WA 98632-2310 Ph: (360) 414-2800 |
News Archive
Professor Matthew Disney of the Department of Chemistry on the Florida campus of The Scripps Research Institute, together with scientists from Mayo Clinic's Florida campus and Johns Hopkins School of Medicine, has been awarded $7.2 million from the National Institute of Neurological Disorders and Stroke of The National Institutes of Health to create new RNA-based treatments for the most common form of amyotrophic lateral sclerosis (ALS), as well as a type of frontotemporal dementia (FTD).
A pair of neurologists at Nationwide Children's Hospital, Monica P. Islam, MD, and E. Steve Roach, MD, are the editors behind "Neurocutaneous Syndromes," a recently published book that highlights the insights of neurocutaneous syndromes research and shows that "classic doctoring" still has a big role to play in diagnosis and treatment.
Depomed, Inc. today announced top line results from the Phase III clinical trial of its Ciprofloxacin GR, an extended release formulation of ciprofloxacin HCl, which is used to treat urinary tract infections. The data confirmed Phase II results, demonstrating that Depomed's once-daily Ciprofloxacin GR eliminated the organisms responsible for urinary tract infections as effectively as twice-daily CIPRO(R), but with fewer gastrointestinal side effects, specifically fewer incidences of nausea and diarrhea.
In this Kaiser Health News consumer column, Michelle Andrews writes: "High-deductible health plans and the health savings accounts (HSAs) that link to them are becoming a familiar fixture on the insurance landscape, even though they get mixed reviews from many consumers and health-policy experts" (Kaiser Health News).
Depression is associated with an increased risk of developing kidney failure in the future, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society Nephrology.
› Verified 8 days ago